Citadel Advisors’s Aprea Therapeutics APRE Stock Holding History

Citadel Advisors’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-16,115	Closed	-$104K	–	14667
2022 Q4	$104K	Sell	16,115 -490	-3%	-$5.17K	﹤0.01%	11168
2022 Q3	$216K	Sell	16,605 -1,690	-9%	-$30K	﹤0.01%	10256
2022 Q2	$271K	Sell	18,295 -65	-0.4%	-$1.5K	﹤0.01%	10030
2022 Q1	$683K	Buy	18,360 +13,750	+298%	+$564K	﹤0.01%	8631
2021 Q4	$265K	Buy	4,610 +2,225	+93%	+$197K	﹤0.01%	11195
2021 Q3	$244K	Buy	2,385 +1,310	+122%	+$119K	﹤0.01%	11526
2021 Q2	$105K	Buy	1,075 +205	+24%	+$18.9K	﹤0.01%	12875
2021 Q1	$89K	Buy	+870	New	+$101K	﹤0.01%	12565

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors's APRE Position: Q2 2026 in Review

Citadel Advisors opened a new position in Aprea Therapeutics (APRE) in Q2 2026: 58,600 shares worth $47K. The stake represents ﹤0.01% of the portfolio and ranks #13143 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in APRE as recently as Q4 2025.

Citadel Advisors first reported a position in APRE in Q4 2019 and has held it in 13 quarters since. The position peaked at $14.2M in Q4 2019. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

Citadel Advisors held 58,600 shares of Aprea Therapeutics worth $47K as of Q2 2026.
Aprea Therapeutics was a new Citadel Advisors position in Q2 2026.
Aprea Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13143 holding.
Citadel Advisors first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 13 quarters since.
Citadel Advisors's Aprea Therapeutics position peaked at $14.2M in Q4 2019.
28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.